On Friday, Exelixis earned an upgrade to its Relative Strength (RS) Rating, from 65 to 72.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if Exelixis can continue to show renewed price strength and hit that benchmark.
Exelixis is not currently offering a proper buying opportunity. See if the stock goes on to form a chart pattern that could spark a new run.
Exelixis posted negative growth for both sales and earnings last quarter.
Exelixis holds the No. 37 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
